Country: Canada
Language: English
Source: Health Canada
PERINDOPRIL ERBUMINE
AURO PHARMA INC
C09AA04
PERINDOPRIL
8MG
TABLET
PERINDOPRIL ERBUMINE 8MG
ORAL
30/100/500
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0127178003; AHFS:
APPROVED
2018-03-07
AURO-PERINDOPRIL PRODUCT MONOGRAPH Page 1 of 67 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AURO-PERINDOPRIL Perindopril Erbumine Tablets Tablets, 2 mg, 4 mg and 8 mg, Oral House Standard Angiotensin Converting Enzyme Inhibitor AURO PHARMA INC. 3700 Steeles Avenue West, Suite # 402 Woodbridge, Ontario, L4L 8K8, Canada. Date of Initial Authorization: January 11, 2018 Date of Revision: June 6, 2023 Submission Control Number: 270817 AURO-PERINDOPRIL PRODUCT MONOGRAPH Page 2 of 67 RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 06/2023 7 WARNING AND PRECAUTIONS 06/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ...................................................................................................................... 4 1.1 Pediatrics (< 18 years of age) ..................................................................................... 4 1.2 Geriatrics (>65 years of age) ...................................................................................... 4 2 CONTRAINDICATIONS ......................................................................................................... 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .................................................................... 5 4 DOSAGE AND ADMINISTRATION ........................................................................................ 5 4.1 Dosing Considerations ............................................................................................... 6 4.2 Recommended Dose and Dosage Adjustment ............................................................ 6 4.4 Administration Read the complete document